# Multicenter validation of the newly developed Concise Objectifiable Risk Evaluation (CORE) score also confirms its ability to complement the Hematopoietic Cell Comorbidity Index (HCT-CI)

**Authors:** Gunnar Weise, Christina Rautenberg, Alexander Denk, Radwan Massoud, Elisabeth Meedt, Daniel Wolff, Thomas Schroeder, Francis Ayuk

PMC · DOI: 10.1038/s41409-025-02778-w · 2025-12-16

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** Multiple Myeloma (MESH:D009101), malignancy (MESH:D009369), AML (MESH:D015470), hematologic malignancies (MESH:D019337), MDS (MESH:D009190), myelodysplastic syndrome and myeloproliferative neoplasms (MESH:D054437), NRM (MESH:D003643), ALL (MESH:D054198), lymphomas (MESH:D008223)
- **Chemicals:** creatinine (MESH:D003404)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12965864/full.md

---
Source: https://tomesphere.com/paper/PMC12965864